Data Set Name,# of Samples,Platform,Reference,Download Link
204,GSE49997,ABI Human Genome Survey Microarray Version 2,"Pils D, Hager G, Tong D, Aust S et al. Validating the impact of a molecular subtype in ovarian cancer on outcomes: a study of the OVCAD Consortium. Cancer Sci 2012 Jul;103(7):1334-41. PMID: 22497737",https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE49997
174,GSE53963,Agilent-014850 Whole Human Genome Microarray 4x44K G4112F ,"Konecny GE, Wang C, Hamidi H, Winterhoff B et al. Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancer. J Natl Cancer Inst 2014 Oct;106(10). PMID: 25269487",https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE53963
185,GSE26712,Affymetrix HG-U133A,"Bonome T, Levine DA, Shih J, Randonovich M et al. A gene signature predicting for survival in suboptimally debulked patients with ovarian cancer. Cancer Res 2008 Jul 1;68(13):5478-86. PMID: 18593951 & Vathipadiekal V, Wang V, Wei W, Waldron L et al. Creation of a Human Secretome: A Novel Composite Library of Human Secreted Proteins: Validation Using Ovarian Cancer Gene Expression Data and a Virtual Secretome Array. Clin Cancer Res 2015 Nov 1;21(21):4960-9. PMID: 25944803",https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE26712
514,TCGA,RNA-seq,"Cancer Genome Atlas (TCGA) Research Network. (2008). Comprehensive genomic characterization defines human glioblastoma genes and core pathways.?Nature,?455(7216), 1061.",http://firebrowse.org/?cohort=BRCA&download_dialog=true
